Ventilator-associated pneumonia surveillance using two methods.


Journal

The Journal of hospital infection
ISSN: 1532-2939
Titre abrégé: J Hosp Infect
Pays: England
ID NLM: 8007166

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 29 11 2019
accepted: 28 01 2020
pubmed: 9 2 2020
medline: 14 1 2021
entrez: 9 2 2020
Statut: ppublish

Résumé

Ventilator-associated pneumonia surveillance is used as a quality indicator due to concerns that some cases may be preventable and may contribute to mortality. Various surveillance criteria exist for the purposes of national reporting, but a large-scale direct comparison has not been conducted. A prospective cohort study applied two routinely used surveillance criteria for ventilator-associated pneumonia from the European Centre for Disease Control and the American Centers for Disease Control to all patients admitted to two large general intensive care units. Diagnostic rates and concordance amongst diagnostic events were compared. A total of 713 at-risk patients were identified during the study period. The European surveillance algorithm returned a rate of 4.6 cases of ventilator-associated pneumonia per 1000 ventilation days (95% confidence interval 3.1-6.6) and the American surveillance system a rate of 5.4 (3.8-7.5). The concordance between diagnostic events was poor (Cohen's Kappa 0.127 (-0.003 to 0.256)). The algorithms yield similar rates, but the lack of event concordance reveals the absence of inter-algorithm agreement for diagnosing ventilator-associated pneumonia, potentially undermining surveillance as an indicator of care quality.

Sections du résumé

BACKGROUND BACKGROUND
Ventilator-associated pneumonia surveillance is used as a quality indicator due to concerns that some cases may be preventable and may contribute to mortality. Various surveillance criteria exist for the purposes of national reporting, but a large-scale direct comparison has not been conducted.
METHODS METHODS
A prospective cohort study applied two routinely used surveillance criteria for ventilator-associated pneumonia from the European Centre for Disease Control and the American Centers for Disease Control to all patients admitted to two large general intensive care units. Diagnostic rates and concordance amongst diagnostic events were compared.
FINDINGS RESULTS
A total of 713 at-risk patients were identified during the study period. The European surveillance algorithm returned a rate of 4.6 cases of ventilator-associated pneumonia per 1000 ventilation days (95% confidence interval 3.1-6.6) and the American surveillance system a rate of 5.4 (3.8-7.5). The concordance between diagnostic events was poor (Cohen's Kappa 0.127 (-0.003 to 0.256)).
CONCLUSIONS CONCLUSIONS
The algorithms yield similar rates, but the lack of event concordance reveals the absence of inter-algorithm agreement for diagnosing ventilator-associated pneumonia, potentially undermining surveillance as an indicator of care quality.

Identifiants

pubmed: 32035121
pii: S0195-6701(20)30044-X
doi: 10.1016/j.jhin.2020.01.020
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

522-528

Informations de copyright

Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Auteurs

T H Craven (TH)

Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK; Clinical Microbiology, NHS Lothian Infection Service, Royal Infirmary of Edinburgh, Edinburgh, UK. Electronic address: Thomas.craven@ed.ac.uk.

G Wojcik (G)

Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK.

J McCoubrey (J)

Health Protection Scotland, Glasgow, UK.

O Brooks (O)

Clinical Microbiology, NHS Lothian Infection Service, Royal Infirmary of Edinburgh, Edinburgh, UK.

E Grant (E)

Western General Hospital, Edinburgh, UK.

S Keating (S)

Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK.

J Reilly (J)

Health Protection Scotland, Glasgow, UK.

I F Laurenson (IF)

Clinical Microbiology, NHS Lothian Infection Service, Royal Infirmary of Edinburgh, Edinburgh, UK.

K Kefala (K)

Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK; Clinical Microbiology, NHS Lothian Infection Service, Royal Infirmary of Edinburgh, Edinburgh, UK.

T S Walsh (TS)

Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; Edinburgh Critical Care Research Group, University of Edinburgh, Edinburgh, UK; Clinical Microbiology, NHS Lothian Infection Service, Royal Infirmary of Edinburgh, Edinburgh, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH